A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy

Valerio Gelfo, Martina Mazzeschi, Giada Grilli, Moshit Lindzen, Spartaco Santi, Gabriele D'Uva, Balázs Győrffy, Andrea Ardizzoni, Yosef Yarden, Mattia Lauriola

Research output: Contribution to journalArticle

Abstract

Cetuximab (CTX) is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), commonly used to treat patients with metastatic colorectal cancer (mCRC). Unfortunately, objective remissions occur only in a minority of patients and are of short duration, with a population of cells surviving the treatment and eventually enabling CTX resistance. Our previous study on CRC xenopatients associated poor response to CTX with increased abundance of a set of pro-inflammatory cytokines, including the interleukins IL-1A, IL-1B and IL-8. Stemming from these observations, our current work aimed to assess the role of IL-1 pathway activity in CTX resistance. We employed a recombinant decoy TRAP IL-1, a soluble protein combining the human immunoglobulin Fc portion linked to the extracellular region of the IL-1-receptor (IL-1R1), able to sequester IL-1 directly from the medium. We generated stable clones expressing and secreting a functional TRAP IL-1 into the culture medium. Our results show that IL-1R1 inhibition leads to a decreased cell proliferation and a dampened MAPK and AKT axes. Moreover, CRC patients not responding to CTX blockage displayed higher levels of IL-1R1 than responsive subjects, and abundant IL-1R1 is predictive of survival in patient datasets specifically for the consensus molecular subtype 1 (CMS1). We conclude that IL-1R1 abundance may represent a therapeutic marker for patients who become refractory to monoclonal antibody therapy, while inhibition of IL-1R1 by TRAP IL-1 may offer a novel therapeutic strategy.

Original languageEnglish
Pages (from-to)1-16
Number of pages16
JournalCancers
Volume10
Issue number10
DOIs
Publication statusPublished - Sep 26 2018

Fingerprint

Interleukin-1 Receptors
Interleukin-1
Epidermal Growth Factor Receptor
Monoclonal Antibodies
Immunoglobulin Fc Fragments
Therapeutics
Interleukins
Interleukin-8
Culture Media
Colorectal Neoplasms
Clone Cells
Cell Proliferation
Cetuximab
Cytokines
Survival
Population
Proteins

Keywords

  • MAPK
  • cetuximab
  • colon cancer
  • colonspheres
  • consensus molecular subtype
  • inflammation
  • resistance

Cite this

Gelfo, V., Mazzeschi, M., Grilli, G., Lindzen, M., Santi, S., D'Uva, G., ... Lauriola, M. (2018). A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy. Cancers, 10(10), 1-16. https://doi.org/10.3390/cancers10100355

A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy. / Gelfo, Valerio; Mazzeschi, Martina; Grilli, Giada; Lindzen, Moshit; Santi, Spartaco; D'Uva, Gabriele; Győrffy, Balázs; Ardizzoni, Andrea; Yarden, Yosef; Lauriola, Mattia.

In: Cancers, Vol. 10, No. 10, 26.09.2018, p. 1-16.

Research output: Contribution to journalArticle

Gelfo, V, Mazzeschi, M, Grilli, G, Lindzen, M, Santi, S, D'Uva, G, Győrffy, B, Ardizzoni, A, Yarden, Y & Lauriola, M 2018, 'A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy', Cancers, vol. 10, no. 10, pp. 1-16. https://doi.org/10.3390/cancers10100355
Gelfo, Valerio ; Mazzeschi, Martina ; Grilli, Giada ; Lindzen, Moshit ; Santi, Spartaco ; D'Uva, Gabriele ; Győrffy, Balázs ; Ardizzoni, Andrea ; Yarden, Yosef ; Lauriola, Mattia. / A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy. In: Cancers. 2018 ; Vol. 10, No. 10. pp. 1-16.
@article{1d9554c02c7944cca4019491cf3ea2c9,
title = "A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy",
abstract = "Cetuximab (CTX) is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), commonly used to treat patients with metastatic colorectal cancer (mCRC). Unfortunately, objective remissions occur only in a minority of patients and are of short duration, with a population of cells surviving the treatment and eventually enabling CTX resistance. Our previous study on CRC xenopatients associated poor response to CTX with increased abundance of a set of pro-inflammatory cytokines, including the interleukins IL-1A, IL-1B and IL-8. Stemming from these observations, our current work aimed to assess the role of IL-1 pathway activity in CTX resistance. We employed a recombinant decoy TRAP IL-1, a soluble protein combining the human immunoglobulin Fc portion linked to the extracellular region of the IL-1-receptor (IL-1R1), able to sequester IL-1 directly from the medium. We generated stable clones expressing and secreting a functional TRAP IL-1 into the culture medium. Our results show that IL-1R1 inhibition leads to a decreased cell proliferation and a dampened MAPK and AKT axes. Moreover, CRC patients not responding to CTX blockage displayed higher levels of IL-1R1 than responsive subjects, and abundant IL-1R1 is predictive of survival in patient datasets specifically for the consensus molecular subtype 1 (CMS1). We conclude that IL-1R1 abundance may represent a therapeutic marker for patients who become refractory to monoclonal antibody therapy, while inhibition of IL-1R1 by TRAP IL-1 may offer a novel therapeutic strategy.",
keywords = "MAPK, cetuximab, colon cancer, colonspheres, consensus molecular subtype, inflammation, resistance",
author = "Valerio Gelfo and Martina Mazzeschi and Giada Grilli and Moshit Lindzen and Spartaco Santi and Gabriele D'Uva and Bal{\'a}zs Győrffy and Andrea Ardizzoni and Yosef Yarden and Mattia Lauriola",
year = "2018",
month = "9",
day = "26",
doi = "10.3390/cancers10100355",
language = "English",
volume = "10",
pages = "1--16",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "10",

}

TY - JOUR

T1 - A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy

AU - Gelfo, Valerio

AU - Mazzeschi, Martina

AU - Grilli, Giada

AU - Lindzen, Moshit

AU - Santi, Spartaco

AU - D'Uva, Gabriele

AU - Győrffy, Balázs

AU - Ardizzoni, Andrea

AU - Yarden, Yosef

AU - Lauriola, Mattia

PY - 2018/9/26

Y1 - 2018/9/26

N2 - Cetuximab (CTX) is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), commonly used to treat patients with metastatic colorectal cancer (mCRC). Unfortunately, objective remissions occur only in a minority of patients and are of short duration, with a population of cells surviving the treatment and eventually enabling CTX resistance. Our previous study on CRC xenopatients associated poor response to CTX with increased abundance of a set of pro-inflammatory cytokines, including the interleukins IL-1A, IL-1B and IL-8. Stemming from these observations, our current work aimed to assess the role of IL-1 pathway activity in CTX resistance. We employed a recombinant decoy TRAP IL-1, a soluble protein combining the human immunoglobulin Fc portion linked to the extracellular region of the IL-1-receptor (IL-1R1), able to sequester IL-1 directly from the medium. We generated stable clones expressing and secreting a functional TRAP IL-1 into the culture medium. Our results show that IL-1R1 inhibition leads to a decreased cell proliferation and a dampened MAPK and AKT axes. Moreover, CRC patients not responding to CTX blockage displayed higher levels of IL-1R1 than responsive subjects, and abundant IL-1R1 is predictive of survival in patient datasets specifically for the consensus molecular subtype 1 (CMS1). We conclude that IL-1R1 abundance may represent a therapeutic marker for patients who become refractory to monoclonal antibody therapy, while inhibition of IL-1R1 by TRAP IL-1 may offer a novel therapeutic strategy.

AB - Cetuximab (CTX) is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), commonly used to treat patients with metastatic colorectal cancer (mCRC). Unfortunately, objective remissions occur only in a minority of patients and are of short duration, with a population of cells surviving the treatment and eventually enabling CTX resistance. Our previous study on CRC xenopatients associated poor response to CTX with increased abundance of a set of pro-inflammatory cytokines, including the interleukins IL-1A, IL-1B and IL-8. Stemming from these observations, our current work aimed to assess the role of IL-1 pathway activity in CTX resistance. We employed a recombinant decoy TRAP IL-1, a soluble protein combining the human immunoglobulin Fc portion linked to the extracellular region of the IL-1-receptor (IL-1R1), able to sequester IL-1 directly from the medium. We generated stable clones expressing and secreting a functional TRAP IL-1 into the culture medium. Our results show that IL-1R1 inhibition leads to a decreased cell proliferation and a dampened MAPK and AKT axes. Moreover, CRC patients not responding to CTX blockage displayed higher levels of IL-1R1 than responsive subjects, and abundant IL-1R1 is predictive of survival in patient datasets specifically for the consensus molecular subtype 1 (CMS1). We conclude that IL-1R1 abundance may represent a therapeutic marker for patients who become refractory to monoclonal antibody therapy, while inhibition of IL-1R1 by TRAP IL-1 may offer a novel therapeutic strategy.

KW - MAPK

KW - cetuximab

KW - colon cancer

KW - colonspheres

KW - consensus molecular subtype

KW - inflammation

KW - resistance

U2 - 10.3390/cancers10100355

DO - 10.3390/cancers10100355

M3 - Article

C2 - 30261609

VL - 10

SP - 1

EP - 16

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 10

ER -